Radius Health, Inc. Announces Pricing of Public Offering

WALTHAM, Mass., July 22, 2015 (GLOBE NEWSWIRE) -- Radius Health, Inc. (NASDAQ: RDUS) (the "Company"), a science-driven biopharmaceutical company focused on developing new therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases, including hormone responsive metastatic breast cancer, today announced that it has priced its public offering of 4,054,054 shares of its common stock at a public offering price of $74.00 per share. In addition, the Company has granted the underwriters an option to purchase up to an additional 608,108 shares of its common stock, exercisable for 30 days. 

J.P. Morgan, BofA Merrill Lynch and Deutsche Bank Securities are acting as joint book-running managers for the offering. Cowen and Company is acting as lead manager.

The offering is being made pursuant to an effective shelf registration statement on Form S-3 filed with the Securities and Exchange Commission on January 20, 2015. This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of shares of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

A preliminary prospectus supplement describing the terms of the offering has been filed with the Securities and Exchange Commission and forms a part of the effective registration statement. Copies of the final prospectus supplement and accompanying prospectus relating to the offering may be obtained, when available, by contacting J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, or by telephone at 866-803-9204, or email at [email protected]; BofA Merrill Lynch, Attention: Prospectus Department, 222 Broadway, New York, NY 10038, email: [email protected]; or Deutsche Bank Securities Inc., Attention: Prospectus Group, 60 Wall Street, New York, NY 10005-2836, via telephone at 800-503-4611 or via e-mail: [email protected].

CONTACT: Investor Relations
         Barbara Ryan
         Investor Relations
         Radius Health, Inc.
         203-274-2825
         [email protected]

You May Also Be Interested In

• Alliance Laundry principal stockholder prices 22.55M share offering
• IM Cannabis plans 30:1 share consolidation to meet Nasdaq listing rule
• Enovix names interim CEO after Raj Talluri resignation